Cancer Research Technology
Log in Register
Menu

AKR1C3 inhibitor CRT0093964 Small Molecule (Tool Compound)
RECENTLY UPDATED

Invented by Dr Laurent Rigoreau from Cancer Research Horizons
Invented at Cancer Research Horizons

Info

Catalogue Number 151880
Antigen/Gene or Protein Targets Type 5 17-β-Hydroxysteroid Dehydrogenase (AKR1C3)
Type Inhibitor
Relevance CRT0093964 is a highly potent and selective inhibitor of the Type 5 17-β-Hydroxysteroid Dehydrogenase (AKR1C3).
On Target IC50 IC50 = 88 nM
Selectivity Displays >100-fold selectivity against AKR1C1, AKR1C2 and AKR1C4. Does not display any COX (cyclooxygenase) inhibition at 10 µM in whole blood assay.
Molecular Formula C15H20CIN3O2
lUPAC 4-(4-Chloro-phenyl)-piperazin-1-yl]-morpholin-4-yl-methanone
Molecular Weight (g/mol) 309.79
Research Area
RECENTLY UPDATED
Cell Signaling & Signal Transduction, Metabolism, Neurobiology
Notes Referred to as A9 in Khanim et al., 2014.

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries
RECENTLY UPDATED

Khanim et al. 2014. Br J Cancer. 110(6):1506-16. PMID: 24569460.

Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.

Europe PMC ID: 24569460


Add a reference

References: 2 entries
RECENTLY UPDATED

Khanim et al. 2014. Br J Cancer. 110(6):1506-16. PMID: 24569460.

Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.


Add a reference